What is SPRB's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.13B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for SPRB?

P/E (TTM) is n/a and 52-week range is $40.33 to $199.20 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s SPRB figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for SPRB?

The company profile lists revenue (TTM) near $5M, net income (TTM) near $-5.30B, EPS (TTM) near $-38.31 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Spruce Biosciences, Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in South San Francisco, California, US, 2.8M shares outstanding, ISIN US85209E2081 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Spruce Biosciences, Inc

$SPRB

Health Care · Biotechnology

IR Run Scenarios

$44.05

-3.27%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Spruce Biosciences, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The company is headquartered in South San Francisco, California and currently employs 8 full-time employees. The company went IPO on 2020-10-09. The company has a diverse portfolio of product candidates addressing diseases with high unmet medical need and clear biology for treatment, for which there are either no approved therapies treating the underlying disease or suboptimal treatment options. Its pipeline consists of TA-ERT, Tildacerfont and Cortibon, and SPR202. TA-ERT is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase. TA-ERT is intended as an enzyme replacement therapy for the treatment of patients with MPS IIIB who lack rhNAGLU enzyme activity. Tildacerfont has the potential to address hyperactive brain corticotropin-releasing factors neurotransmission and aberrant functioning of the hypothalamus-pituitary-adrenal axis in patients with MDD. SPR202 focuses on the treatment of Congenital Adrenal Hyperplasia and other indications.

Employees

Website

sprucebio.com/

IPO

2020-10-09

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)